The combination of ALK and MET inhibitors is emerging as a plausible efficient combination, since MET amplification has been detected in 15% of tumor biopsies from patients relapsing on next‐generation ALK inhibitors, including 12% and 22% of biopsies from patients progressing on second‐generation inhibitors or lorlatinib, respectively [104]. Here, MET is linked to neoplasm.